233 related articles for article (PubMed ID: 30194476)
1. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
2. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
3. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT
Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
5. A novel approach to inhibit bone resorption: exosite inhibitors against cathepsin K.
Panwar P; Søe K; Guido RV; Bueno RV; Delaisse JM; Brömme D
Br J Pharmacol; 2016 Jan; 173(2):396-410. PubMed ID: 26562357
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible.
Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT
Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310
[TBL] [Abstract][Full Text] [Related]
7. The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.
Fuller K; Lindstrom E; Edlund M; Henderson I; Grabowska U; Szewczyk KA; Moss R; Samuelsson B; Chambers TJ
Bone; 2010 May; 46(5):1400-7. PubMed ID: 20097319
[TBL] [Abstract][Full Text] [Related]
8. An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice.
Panwar P; Xue L; Søe K; Srivastava K; Law S; Delaisse JM; Brömme D
J Bone Miner Res; 2017 Dec; 32(12):2415-2430. PubMed ID: 28745432
[TBL] [Abstract][Full Text] [Related]
9. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
11. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
12. Azanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.
Ren ZY; Machuca-Gayet I; Domenget C; Buchet R; Wu Y; Jurdic P; Mebarek S
PLoS One; 2015; 10(7):e0132513. PubMed ID: 26168340
[TBL] [Abstract][Full Text] [Related]
13. Real-time analysis of osteoclast resorption and fusion dynamics in response to bone resorption inhibitors.
Panwar P; Olesen JB; Blum G; Delaisse JM; Søe K; Brömme D
Sci Rep; 2024 Mar; 14(1):7358. PubMed ID: 38548807
[TBL] [Abstract][Full Text] [Related]
14. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
15. Cathepsin K inhibitors increase distal femoral bone mineral density in rapidly growing rabbits.
Pennypacker BL; Oballa RM; Levesque S; Kimmel DB; Duong LT
BMC Musculoskelet Disord; 2013 Dec; 14():344. PubMed ID: 24321244
[TBL] [Abstract][Full Text] [Related]
16. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of ectosteric antiresorptive agents for bone.
Panwar P; Law S; Jamroz A; Azizi P; Zhang D; Ciufolini M; Brömme D
Br J Pharmacol; 2018 Mar; 175(6):902-923. PubMed ID: 29278432
[TBL] [Abstract][Full Text] [Related]
17. Effect of SI-591, a new class of cathepsin K inhibitor with peptidomimetic structure, on bone metabolism in vitro and in vivo.
Fujii T; Ishikawa M; Kubo A; Tanaka Y
Bone; 2015 Dec; 81():427-434. PubMed ID: 26297834
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
19. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
20. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
